0001157523-22-001444.txt : 20221031 0001157523-22-001444.hdr.sgml : 20221031 20221031170042 ACCESSION NUMBER: 0001157523-22-001444 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20221026 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221031 DATE AS OF CHANGE: 20221031 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HERBALIFE NUTRITION LTD. CENTRAL INDEX KEY: 0001180262 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32381 FILM NUMBER: 221346896 BUSINESS ADDRESS: STREET 1: P.O. BOX 309GT STREET 2: UGLAND HOUSE, SOUTH CHURCH STREET CITY: GEORGE TOWN STATE: E9 ZIP: 00000 BUSINESS PHONE: 310 410 9600 MAIL ADDRESS: STREET 1: P.O. BOX 309GT STREET 2: UGLAND HOUSE, SOUTH CHURCH STREET CITY: GEORGE TOWN STATE: E9 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: HERBALIFE LTD. DATE OF NAME CHANGE: 20041214 FORMER COMPANY: FORMER CONFORMED NAME: WH HOLDINGS CAYMAN ISLANDS LTD DATE OF NAME CHANGE: 20020814 8-K 1 a52955832.htm HERBALIFE NUTRITION LTD. 8-K


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
 


FORM 8-K


 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): October 26, 2022


 
Herbalife Nutrition Ltd.
(Exact Name of Registrant as Specified in Charter)
 

 
Cayman Islands
1-32381
98-0377871
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
   
P.O. Box 309, Ugland House
Grand Cayman
Cayman Islands
KY1-1104
(Address of Principal Executive Offices)
(Zip Code)
 
Registrant’s telephone number, including area code: c/o (213) 745-0500
 
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)


 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Shares, par value $0.0005 per share
HLF
New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 
Emerging growth company 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  


Item 2.02.  Results of Operations and Financial Condition.

On October 31, 2022, Herbalife Nutrition Ltd. (the “Company”) issued a press release announcing its financial results for its third fiscal quarter ended September 30, 2022. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information contained in this Item 2.02 and Exhibit 99.1 attached to this report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 5.02.    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Chairman and CEO Transition

On October 27, 2022, Dr. John Agwunobi stepped down as the Company’s Chairman and Chief Executive Officer and as a member of the Board of Directors of the Company (the “Board”), effective October 27, 2022 (the “Effective Date”). Dr. Agwunobi’s transition was not due to any disagreements with the Company.

On October 29, 2022, the Board adopted resolutions to reduce the size of the Board from eleven to ten members, and, as of the Effective Date, appointed Michael O. Johnson as the Company’s Chairman and interim Chief Executive Officer.

Mr. Johnson, 68, is a current member of the Board since April 2022, and from April 2003 to April 2020. He also was the Chairman of the Board from 2007 to April 2020, and the Company’s Executive Chairman from June 2017 until January 2019. Additionally, Mr. Johnson previously served as the Company’s Chief Executive Officer from April 2003 until May 2017, and then from January 2019 to March 2020.  Mr. Johnson is not a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. The Company will disclose Mr. Johnson’s compensation as interim Chief Executive Officer, once determined, in a Current Report on Form 8-K.

A copy of the press release issued by the Company on October 31, 2022 regarding this transition is attached as Exhibit 99.2 to this current report.

In connection with this transition, Herbalife International of America, Inc., a wholly-owned subsidiary of the Company, entered into a Separation Agreement and General Release with Dr. Agwunobi, dated October 31, 2022 (the “Agreement”). Pursuant to the terms of the Agreement, Dr. Agwunobi: (i) will not solicit any of the Company’s employees, distributors or customers between October 31, 2022 and December 31, 2023; (ii) will not disparage, defame or make any negative or derogatory statements about the Company or any of its affiliates, past or current officers, directors, employees or members; and (iii) will cooperate with the Company in connection with any internal or external investigations and legal matters. Additionally, the Agreement includes a customary general release by Dr. Agwunobi of all waivable claims against the Company and its affiliates and reinforces Dr. Agwunobi’s obligation to not disclose any confidential information. The foregoing items are collectively referred to as the “Consideration Requirements.” In exchange for the foregoing, the Company shall pay Dr. Agwunobi remuneration in the amount of $2,261,538, which represents: (i) the portion of Dr. Agwunobi’s base salary that he would have earned if he had remained employed by the Company through December 31, 2022; and (ii) an amount equal to two years of Dr. Agwunobi’s base salary as of October 31, 2022. Dr. Agwunobi’s unvested Performance Stock Units granted in 2020 will remain effective following October 31, 2022 and will be settled on the dates and in the amounts that they would have been settled as if he had remained employed by the Company through the applicable vesting dates. Breach of any of the Consideration Requirements will allow the Company to terminate any payment or consideration, and recoup any previously paid amounts, under the Agreement.

NEO Departure

Further, on October 26, 2022, Alan Hoffman, the Company’s Executive Vice President of Global Corporate Affairs, and a named executive officer of the Company, notified the Company of his intent to resign from the Company, effective November 4, 2022, to pursue another opportunity.

Item 7.01.   Regulation FD Disclosure.

Earnings Call Investor Slides

The Company intends to reference investor slides during the Company’s earnings conference call to discuss its financial results for its third fiscal quarter ended September 30, 2022. A copy of the presentation can be accessed in the “News and Events” section on the investor relations section of the Company’s website at http://ir.herbalife.com under the heading “IR Calendar”.

The information included in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.


Item 9.01.  Financial Statements and Exhibits.

(d)
Exhibits.

   
   
104
Cover Page Interactive Data File – The cover page from the Company’s Current Report on Form 8-K filed on October 31, 2022 is formatted in Inline XBRL (included as Exhibit 101).


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Herbalife Nutrition Ltd.
     
October 31, 2022
By:
/s/ Henry C. Wang
 
 
Name:
Henry C. Wang
 
 
Title:
EVP, General Counsel and Corporate Secretary


EX-99.1 2 a52955832_ex991.htm EXHIBIT 99.1
Exhibit 99.1

Herbalife Nutrition Reports Third Quarter 2022 Results, Withdraws Full Year 2022 Guidance and Announces CEO Transition

LOS ANGELES--(BUSINESS WIRE)--October 31, 2022--Herbalife Nutrition Ltd. (NYSE: HLF) today reported financial results for the third quarter ended September 30, 2022:

“Building momentum will be my top focus as I continue to work with this talented management team.” - Michael O. Johnson, Chairman and Interim CEO of Herbalife Nutrition

Highlights

  • Third quarter 2022 net sales of $1.3 billion, a 9.5% decrease compared to the third quarter 2021. On a constant currency basis1, net sales declined 3.5% compared to the prior year period.
  • Third quarter 2022 reported diluted EPS of $0.83 and adjusted2 diluted EPS of $0.91, compared to third quarter 2021 reported and adjusted2 diluted EPS of $1.09 and $1.21, respectively.
  • Third quarter 2022 reported net income of $82.2 million and adjusted2 EBITDA of $182.8 million.
  • During the third quarter, the Company reduced its debt levels by paying down $50 million of its revolving credit facility.
  • Given the rapidly shifting macroeconomic sentiment and backdrop, as well as increased volatility in the marketplace, the Company is withdrawing FY 2022 guidance. The Company will periodically reassess its ability to provide guidance when we believe future performance can be reasonably estimated.
  • Michael O. Johnson announced as Chairman and interim CEO. Please refer to separate press release for more information related to the CEO transition.

_______________________________

1 Growth/decline in net sales excluding the effects of foreign exchange is based on “net sales in local currency,” a non-GAAP financial measure. See Schedule A – “Reconciliation of Non-GAAP Financial Measures” for a discussion of why we believe adjusting for the effects of foreign exchange is useful.

2 Adjusted diluted EPS and adjusted EBITDA are non-GAAP measures. See Schedule A – “Reconciliation of Non-GAAP Financial Measures” for a detailed reconciliation of these measures to the most directly comparable GAAP measure, and a discussion of why we believe these non-GAAP measures are useful.


Management Commentary

Herbalife Nutrition reported net sales of $1.3 billion for the third quarter of 2022, a decrease of 9.5% compared to the prior year, which was below the Company’s expectations. The Company believes that macroeconomic inflationary pressures challenged Members’ operations and customer demand during the quarter. Net sales were also negatively impacted due to unfavorable geographic mix of revenue as well as the strengthening of the U.S. dollar, which drove a significant currency headwind compared to net sales the prior year.

Management took decisive actions to execute on expense management initiatives that benefited net income and also contributed to an adjusted1 EBITDA and adjusted1 EPS that were above or near the high-end of the Company’s Q3 guidance range. Additionally, during the third quarter, the Company strategically reduced $50 million of its outstanding debt.

From a global perspective, some of the Company’s underlying business trends and KPIs remained largely stabilized compared to Q2 levels. Worldwide active sales leaders, and new distributors and preferred customers, were slightly improved from Q2 levels. The global metrics were supported by significant strength in India and management is keenly focused on improving distributor metrics outside of India.

As such, the Company is rolling out a new campaign focused on driving new distributors to the Company. This collaboration with the Company’s independent distributors has resulted in market-specific initiatives designed to attract additional distributors to join the company in both the short and long-term. The Company is also supporting Members with the resumption of in-person events, product line expansions, and the deployment of enhanced technology tools to support their businesses.

The sales trends that softened through the third quarter are expected to continue into the fourth quarter were impacted by the challenging macroenomic landscape. Given the rapidly shifting macroeconomic sentiment and backdrop, as well as increased volatility in the marketplace, the Company is withdrawing FY 2022 guidance.

As the Company continues to navigate the macro backdrop, profit protection initiatives remain a focal point for management. At the same time, the Company continues to invest for future growth, including its digital transformation, the Herbalife ONE platform, in addition to the development and launch of new products around the world.

“Over our 42-year history we have overcome numerous macroeconomic challenges, and many of our distributors have developed new successful sales strategies and seen positive longer-term impacts on their organizations as a result of these times, as new individuals look to the Herbalife Nutrition business opportunity as a way to supplement their income,” said CEO, Michael O. Johnson. “We remain confident that the resilience of our business model, the entrepreneurial spirit of our independent distributors, the growth profile of our product categories, and the strategic actions we are taking will help us emerge from the current environment stronger than ever.”


Third Quarter 2022 Key Metrics

Regional Net Sales and Foreign Exchange (“FX”) Impact

Region

Reported Net
Sales
3Q’22 (mil)

Growth/Decline
including FX
vs. 3Q’21

Growth/Decline
excluding FX
vs. 3Q’21 (a) 3

Asia Pacific

$ 431.7

9.7%

17.3%

North America

$ 317.5

(10.5%)

(10.4%)

EMEA

$ 247.7

(23.1%)

(9.4%)

Latin America(b)

$ 187.6

(9.2%)

(6.7%)

China

$ 110.6

(28.2%)

(24.4%)

Worldwide Total

$ 1,295.1

(9.5%)

(3.5%)

(a) Growth/decline in net sales excluding the effects of foreign exchange is based on “net sales in local currency,” a non-GAAP financial measure. See Schedule A – “Reconciliation of Non-GAAP Financial Measures” for a discussion of why we believe adjusting for the effects of foreign exchange is useful.

(b) During the third quarter of 2022, the Company combined its Mexico and South and Central America regions into one geographic region now named Latin America. Historical information has been reclassified to conform with the current period geographic presentation.

Regional Volume Point Metrics

 

Volume Points

Region

3Q’22 (mil)

Yr/Yr % Chg

Asia Pacific

561.9

14.8%

North America

335.3

(23.5%)

EMEA

307.5

(21.2%)

Latin America(b)

273.2

(17.9%)

China

77.8

(15.1%)

Worldwide Total

1,555.7

(10.7%)

Outlook

Given the rapidly shifting macroeconomic sentiment and backdrop, as well as increased volatility in the marketplace, the Company is withdrawing FY 2022 guidance. The Company will periodically reassess its ability to provide guidance when we believe future performance can be reasonably estimated.


Earnings Conference Call

Herbalife Nutrition senior management will host an investor conference call to discuss its recent financial results and provide an update on current business trends on Monday, October 31st, 2022, at 2:30 p.m. PT (5:30 p.m. ET).

Participants will need to register to receive dial-in information to the call, and may do so by visiting the investor relations section of the Company’s website at http://ir.herbalife.com. Additionally, live audio of the conference call will be simultaneously webcast at https://edge.media-server.com/mmc/p/bvzrmiar. Senior management also plans to reference slides during the call, which will also be available on the investor relation’s section of the Company’s website.

An audio replay will be available following the completion of the conference call, and the webcast of the teleconference will be archived and available on the Company’s investor relations site.

About Herbalife Nutrition Ltd.

Herbalife Nutrition (NYSE: HLF) is a global nutrition company that has been changing people's lives with great nutrition products and a business opportunity for its independent distributors since 1980. The Company offers science-backed products to consumers in 95 markets by entrepreneurial distributors who provide one-on-one coaching and a supportive community that inspires their customers to embrace a healthier, more active lifestyle. Through the Company’s commitment to nourish people, communities and our planet, Herbalife Nutrition pledges to achieve 50 million positive impacts – tangible acts of good – by 2030, its 50th anniversary.

For more information, please visit IAmHerbalifeNutrition.com and follow us @Herbalife.

Herbalife Nutrition also encourages investors to visit its investor relations website at ir.herbalife.com as financial and other information is posted.


Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Although we believe that the expectations reflected in any of our forward-looking statements are reasonable, actual results or outcomes could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and to inherent risks and uncertainties, many of which are beyond our control. Additionally, many of these risks and uncertainties are, and may continue to be, amplified by the COVID-19 pandemic. Important factors that could cause our actual results, performance and achievements, or industry results to differ materially from estimates or projections contained in or implied by our forward-looking statements include the following:

  • the potential impacts of the COVID-19 pandemic and current global economic conditions, including inflation, on us; our Members, customers, and supply chain; and the world economy;
  • our ability to attract and retain Members;
  • our relationship with, and our ability to influence the actions of, our Members;
  • our noncompliance with, or improper action by our employees or Members in violation of, applicable U.S. and foreign laws, rules, and regulations;
  • adverse publicity associated with our Company or the direct-selling industry, including our ability to comfort the marketplace and regulators regarding our compliance with applicable laws;
  • changing consumer preferences and demands and evolving industry standards, including with respect to climate change, sustainability, and other environmental, social, and governance, or ESG, matters;
  • the competitive nature of our business and industry;
  • legal and regulatory matters, including regulatory actions concerning, or legal challenges to, our products or network marketing program and product liability claims;
  • the Consent Order entered into with the FTC, the effects thereof and any failure to comply therewith;
  • risks associated with operating internationally and in China;
  • our ability to execute our growth and other strategic initiatives, including implementation of our transformation program and increased penetration of our existing markets;
  • any material disruption to our business caused by natural disasters, other catastrophic events, acts of war or terrorism, including the war in Ukraine, cybersecurity incidents, pandemics, and/or other acts by third parties;
  • our ability to adequately source ingredients, packaging materials, and other raw materials and manufacture and distribute our products;
  • our reliance on our information technology infrastructure;
  • noncompliance by us or our Members with any privacy laws, rules, or regulations or any security breach involving the misappropriation, loss, or other unauthorized use or disclosure of confidential information;
  • contractual limitations on our ability to expand or change our direct-selling business model;
  • the sufficiency of our trademarks and other intellectual property;
  • product concentration;
  • our reliance upon, or the loss or departure of any member of, our senior management team;
  • restrictions imposed by covenants in the agreements governing our indebtedness;
  • risks related to our convertible notes;
  • changes in, and uncertainties relating to, the application of transfer pricing, income tax, customs duties, value added taxes, and other tax laws, treaties, and regulations, or their interpretation;
  • our incorporation under the laws of the Cayman Islands; and
  • share price volatility related to, among other things, speculative trading and certain traders shorting our common shares.

We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.


Results of Operations

Herbalife Nutrition Ltd. and Subsidiaries
Condensed Consolidated Statements of Income
(In millions, except per share amounts)








 

Three Months Ended

 

Nine Months Ended



9/30/2022


9/30/2021


9/30/2022


9/30/2021



(unaudited)
North America

$

317.5


$

354.8


$

987.2

 


$

1,126.6

 


EMEA

 

247.7


 

321.9


 

831.7

 


 

1,043.8

 


Asia Pacific

 

431.7


 

393.5


 

1,290.1

 


 

1,188.8

 


Latin America

 

187.6


 

206.7


 

594.7

 


 

626.5

 


China

 

110.6


 

154.0


 

319.9

 


 

499.1

 


Worldwide Net Sales

 

1,295.1


 

1,430.9


 

4,023.6

 


 

4,484.8

 


Cost of Sales

 

285.1


 

305.2


 

908.0

 


 

942.7

 


Gross Profit

 

1,010.0


 

1,125.7


 

3,115.6

 


 

3,542.1

 


Royalty Overrides

 

414.4


 

450.0


 

1,301.1

 


 

1,409.8

 


Selling, General, and Administrative Expenses

 

448.2


 

486.3


 

1,373.1

 


 

1,498.9

 


Other Operating Income (1)

 

-


 

-


 

(14.9

)


 

(16.4

)


Operating Income

 

147.4


 

189.4


 

456.3

 


 

649.8

 


Interest Expense, net

 

34.5


 

37.7


 

95.9

 


 

112.0

 


Other expense, net (2)

 

-


 

-


 

-

 


 

24.6

 


Income Before Income Taxes

 

112.9


 

151.7


 

360.4

 


 

513.2

 


Income Taxes

 

30.7


 

34.3


 

93.5

 


 

104.2

 


Net Income

$

82.2


$

117.4


$

266.9

 


$

409.0

 










 
Weighted-Average Shares Outstanding:







Basic

 

98.0


 

105.5


 

98.7

 


 

107.3

 


Diluted

 

98.8


 

107.8


 

99.7

 


 

109.8

 










 
Earnings Per Share:







Basic

$

0.84


$

1.11


$

2.70

 


$

3.81

 


Diluted

$

0.83


$

1.09


$

2.68

 


$

3.73

 
















 
(1) Other Operating Income for the nine months ended September 30, 2022 and September 30, 2021 relates to certain China government grant income.
(2) Other Expense, net for the nine months ended September 30, 2021 relates to loss on the extinguishment of the 2026 Notes.


Herbalife Nutrition Ltd. and Subsidiaries

Condensed Consolidated Balance Sheets
(In millions)


Sep 30,

 

Dec 31,


 

2022

 


 

2021

 




 
ASSETS


Current Assets:


Cash and cash equivalents

$

532.5

 


$

601.5

 

Receivables, net

 

85.0

 


 

66.9

 

Inventories

 

537.0

 


 

575.7

 

Prepaid expenses and other current assets

 

229.2

 


 

187.7

 

Total Current Assets

 

1,383.7

 


 

1,431.8

 




 
Property, plant and equipment, net

 

467.8

 


 

442.1

 

Operating lease right-of-use assets

 

200.7

 


 

220.0

 

Marketing-related intangibles and other intangible assets, net

 

316.1

 


 

317.3

 

Goodwill

 

87.6

 


 

95.4

 

Other assets

 

269.2

 


 

313.2

 

Total Assets

$

2,725.1

 


$

2,819.8

 




 
LIABILITIES AND SHAREHOLDERS' DEFICIT


Current Liabilities:


Accounts payable

$

84.5

 


$

92.0

 

Royalty overrides

 

329.0

 


 

363.2

 

Current portion of long-term debt

 

29.5

 


 

29.4

 

Other current liabilities

 

542.5

 


 

595.8

 

Total Current Liabilities

 

985.5

 


 

1,080.4

 




 
Non-current liabilities:


Long-term debt, net of current portion

 

2,725.0

 


 

2,733.2

 

Non-current operating lease liabilities

 

187.8

 


 

201.2

 

Other non-current liabilities

 

188.7

 


 

196.5

 

Total Liabilities

 

4,087.0

 


 

4,211.3

 




 
Commitments and Contingencies





 
Shareholders' deficit:


Common shares

 

0.1

 


 

0.1

 

Paid-in capital in excess of par value

 

181.0

 


 

318.1

 

Accumulated other comprehensive loss

 

(284.3

)


 

(211.8

)

Accumulated deficit

 

(1,258.7

)


 

(1,169.0

)

Treasury stock

 

-

 


 

(328.9

)

Total Shareholders' Deficit

 

(1,361.9

)


 

(1,391.5

)




 
Total Liabilities and Shareholders' Deficit

$

2,725.1

 


$

2,819.8

 








 

Herbalife Nutrition Ltd. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(In millions)


Nine Months Ended



9/30/2022


9/30/2021


CASH FLOWS FROM OPERATING ACTIVITIES:



Net income

$

266.9

 


$

409.0

 


Adjustments to reconcile net income to net cash provided by



operating activities:



Depreciation and amortization

 

87.2

 


 

80.1

 


Share-based compensation expenses

 

37.5

 


 

42.3

 


Non-cash interest expense

 

5.0

 


 

22.4

 


Deferred income taxes

 

(11.5

)


 

2.9

 


Inventory write-downs

 

29.2

 


 

16.9

 


Foreign exchange transaction (gain) loss

 

10.0

 


 

10.5

 


Loss on extinguishment of debt

 

-

 


 

24.6

 


Other

 

(15.1

)


 

1.0

 


Changes in operating assets and liabilities:



Receivables

 

(23.9

)


 

(6.7

)


Inventories

 

(37.4

)


 

(92.2

)


Prepaid expenses and other current assets

 

(26.1

)


 

(68.1

)


Accounts payable

 

(3.7

)


 

11.8

 


Royalty overrides

 

(16.8

)


 

(1.7

)


Other current liabilities

 

(21.8

)


 

(86.2

)


Other

 

19.4

 


 

8.3

 


NET CASH PROVIDED BY OPERATING ACTIVITIES

 

298.9

 


 

374.9

 






 
CASH FLOWS FROM INVESTING ACTIVITIES:



Purchases of property, plant and equipment

 

(113.6

)


 

(104.5

)


Other

 

0.2

 


 

(4.4

)


NET CASH USED IN INVESTING ACTIVITIES

 

(113.4

)


 

(108.9

)






 
CASH FLOWS FROM FINANCING ACTIVITIES:



Borrowings from senior secured credit facility, net of discount

 

433.0

 


 

531.1

 


Principal payments on senior secured credit facility and other debt

 

(505.0

)


 

(416.0

)


Proceeds from senior notes

 

-

 


 

600.0

 


Repayment of senior notes

 

-

 


 

(420.7

)


Debt issuance costs

 

-

 


 

(8.4

)


Share repurchases

 

(146.6

)


 

(909.2

)


Other

 

3.4

 


 

3.2

 


NET CASH USED IN FINANCING ACTIVITIES

 

(215.2

)


 

(620.0

)


EFFECT OF EXCHANGE RATE CHANGES ON CASH, CASH EQUIVALENTS, AND RESTRICTED CASH

 

(40.0

)


 

(13.0

)


NET CHANGE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH

 

(69.7

)


 

(367.0

)


CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, BEGINNING OF PERIOD

 

610.4

 


 

1,054.0

 


CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, END OF PERIOD

$

540.7

 


$

687.0

 










 

Supplemental Information

SCHEDULE A: RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

(Unaudited and unreviewed), (All tables provide Dollars in millions, except per Share Data)

Adjusted Net Income, Adjusted Diluted EPS and Adjusted EBITDA

In addition to its reported results calculated in accordance with GAAP, the Company has included in this release adjusted net income, adjusted diluted EPS and adjusted EBITDA, performance measures that the Securities and Exchange Commission defines as “non-GAAP financial measures.” Adjusted net income, adjusted diluted EPS and adjusted EBITDA exclude the impact of certain unusual or non-recurring items such as non-cash interest expense and amortization associated with the Company’s convertible notes, expenses related to regulatory inquiries and legal accruals, debt issuance costs and losses on extinguishment of debt, expenses related to COVID-19 pandemic, non-income tax items, expenses related to transformation program, and expenses related to digital technology program, as further detailed in the reconciliations below.

Management believes that such non-GAAP financial measures, when read in conjunction with the Company’s reported results, calculated in accordance with GAAP, can provide useful supplemental information for investors because they facilitate a period to period comparative assessment of the Company’s operating performance relative to its performance based on reported results under GAAP, while isolating the effects of some items that vary from period to period without any correlation to core operating performance and eliminate certain charges that management believes do not reflect the Company’s operations and underlying operational performance. The Company’s definition and calculation as set forth in the tables below of adjusted net income, adjusted diluted EPS and adjusted EBITDA may not be comparable to similarly titled measures used by other companies because other companies may not calculate them in the same manner as the Company does and should not be viewed in isolation from nor as alternatives to net income or diluted EPS calculated in accordance with GAAP.

Currency Fluctuation

Our international operations have provided and will continue to provide a significant portion of our total net sales. As a result, total net sales will continue to be affected by fluctuations in the U.S. dollar against foreign currencies. In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, in addition to comparing the percent change in net sales from one period to another in U.S. dollars, we also compare the percent change in net sales from one period to another period using “net sales in local currency.” Net sales in local currency is not a measure presented in accordance with U.S. GAAP. Net sales in local currency removes from net sales in U.S. dollars the impact of changes in exchange rates between the U.S. dollar and the local currencies of our foreign subsidiaries, by translating the current period net sales into U.S. dollars using the same foreign currency exchange rates that were used to translate the net sales for the previous comparable period. We believe presenting net sales in local currency is useful to investors because it allows a meaningful comparison of net sales of our foreign operations from period to period. However, net sales in local currency should not be considered in isolation or as an alternative to net sales in U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.


The following is a reconciliation of net income, presented and reported in accordance with U.S. generally accepted accounting principles, to net income adjusted for certain items:


Three Months Ended

 

Nine Months Ended


9/30/2022

 

9/30/2021

 

9/30/2022

 

9/30/2021


(in millions)







 
Net income, as reported

$

82.2


$

117.4

 


$

266.9

 


$

409.0

 

Non-cash interest expense and amortization of non-cash issuance costs (1) (2) (3)

 

-


 

6.0

 


 

-

 


 

17.6

 

Debt issuance costs related to the senior secured credit facility amendment (1) (2) (4)

 

-


 

0.6

 


 

-

 


 

1.7

 

Net expenses related to COVID-19 pandemic (1) (2)

 

0.5


 

2.5

 


 

3.8

 


 

11.8

 

Expenses related to transformation program (1) (2)

 

2.9


 

3.9

 


 

7.7

 


 

7.6

 

Russia-Ukraine conflict charges (1) (2)

 

0.1


 

-

 


 

5.5

 


 

-

 

Loss on extinguishment of debt (1) (2) (5)

 

-


 

-

 


 

-

 


 

24.6

 

Non-income tax items, net (1) (2) (6)

 

-


 

-

 


 

-

 


 

(7.4

)

Digital technology program costs (1) (2)

 

3.3


 

-

 


 

3.3

 


 

-

 

Income tax adjustments for above items (1) (2)

 

1.0


 

(0.2

)


 

(1.4

)


 

(6.2

)

Net income, as adjusted (7)

$

90.0


$

130.2

 


$

285.8

 


$

458.7

 















 

The following is a reconciliation of diluted earnings per share, presented and reported in accordance with U.S. generally accepted accounting principles, to diluted earnings per share adjusted for certain items:


Three Months Ended
Nine Months Ended

9/30/2022
9/30/2021
9/30/2022
9/30/2021

(per share)







 
Diluted earnings per share, as reported

$

0.83


$

1.09


$

2.68

 


$

3.73

 

Non-cash interest expense and amortization of non-cash issuance costs (1) (2) (3)

 

-


 

0.06


 

-

 


 

0.16

 

Debt issuance costs related to the senior secured credit facility amendment (1) (2) (4)

 

-


 

0.01


 

-

 


 

0.02

 

Net expenses related to COVID-19 pandemic (1) (2)

 

0.01


 

0.02


 

0.04

 


 

0.11

 

Expenses related to transformation program (1) (2)

 

0.03


 

0.04


 

0.08

 


 

0.07

 

Russia-Ukraine conflict charges (1) (2)

 

-


 

-


 

0.06

 


 

-

 

Loss on extinguishment of debt (1) (2) (5)

 

-


 

-


 

-

 


 

0.22

 

Non-income tax items, net (1) (2) (6)

 

-


 

-


 

-

 


 

(0.07

)

Digital technology program costs (1) (2)

 

0.03


 

-


 

0.03

 


 

-

 

Income tax adjustments for above items (1) (2)

 

0.01


 

-


 

(0.01

)


 

(0.06

)

Adjusted diluted earnings per share (7)

$

0.91


$

1.21


$

2.87

 


$

4.18

 








 

The following is a reconciliation of net income, presented and reported in accordance with U.S. generally accepted accounting principles, to EBITDA and adjusted EBITDA:


Three Months Ended
Nine Months Ended

9/30/2022
9/30/2021
9/30/2022
9/30/2021

(in millions)








 
Net income, as reported

$

82.2


$

117.4


$

266.9


$

409.0

 


Interest Expense, net

 

34.5


 

37.7


 

95.9


 

112.0

 


Income Taxes

 

30.7


 

34.3


 

93.5


 

104.2

 


Depreciation and amortization

 

28.6


 

26.6


 

87.2


 

80.1

 


EBITDA

$

176.0


$

216.0


$

543.5


$

705.3

 


Net expenses related to COVID-19 pandemic (1) (2)

 

0.5


 

2.5


 

3.8


 

11.8

 


Expenses related to transformation program (1) (2)

 

2.9


 

3.9


 

7.7


 

7.6

 


Russia-Ukraine conflict charges (1) (2)

 

0.1


 

-


 

5.5


 

-

 


Loss on extinguishment of debt (1) (2) (5)

 

-


 

-


 

-


 

24.6

 


Non-income tax items, net (1) (2) (6)

 

-


 

-


 

-


 

(7.4

)


Digital technology program costs (1) (2)

 

3.3


 

-


 

3.3


 

-

 


Adjusted EBITDA

$

182.8


$

222.4


$

563.8


$

741.9

 










 

(1) Based on interim income tax reporting rules, these expenses are not considered discrete items. The tax effect of the adjustments between our GAAP and non-GAAP results takes into account the tax treatment and related tax rate(s) that apply to each adjustment in the applicable tax jurisdiction(s).
(2) Excludes tax (benefit)/expense as follows:

Three Months Ended
Nine Months Ended

9/30/2022
9/30/2021
9/30/2022
9/30/2021

(in millions)







 
Non-cash interest expense and amortization of non-cash issuance costs

$

-


$

0.5

 


$

-

 


 

0.7

 

Debt issuance costs related to the senior secured credit facility amendment

 

-


 

(0.1

)


 

-

 


 

(0.3

)

Net expenses related to COVID-19 pandemic

 

-


 

(0.2

)


 

(0.7

)


 

(2.1

)

Expenses related to transformation program

 

0.1


 

(0.2

)


 

(0.4

)


 

(0.7

)

Russia-Ukraine conflict charges

 

-


 

-

 


 

(1.2

)


 

-

 

Loss on extinguishment of debt

 

-


 

(0.2

)




 

(5.5

)

Non-income tax items, net

 

-


 

0.1

 


 

-

 


 

1.8

 

Digital technology program costs

 

0.9


 

-

 


 

0.9

 


 

-

 

Total income tax adjustments (7)

$

1.0


$

(0.2

)


$

(1.4

)


$

(6.2

)








 

Three Months Ended
Nine Months Ended

9/30/2022
9/30/2021
9/30/2022
9/30/2021

(per share)







 
Non-cash interest expense and amortization of non-cash issuance costs

 

-


$

-

 


 

-

 


 

0.01

 

Debt issuance costs related to the senior secured credit facility amendment

 

-


 

-

 


 

-

 


 

-

 

Net expenses related to COVID-19 pandemic

 

-


 

-

 


 

(0.01

)


 

(0.02

)

Expenses related to transformation program

 

-


 

-

 


 

-

 


 

(0.01

)

Russia-Ukraine conflict charges

 

-


 

-

 


 

(0.01

)


 

-

 

Loss on extinguishment of debt

 

-


 

-

 


 

-

 


 

(0.05

)

Non-income tax items, net

 

-


 

-

 


 

-

 


 

0.02

 

Digital technology program costs

 

0.01


 

-

 


 

0.01

 


 

-

 

Total income tax adjustments (7)

$

0.01


$

-

 


$

(0.01

)


$

(0.06

)








 
(3) Relates to non-cash expense on the Company's 2.625% convertible senior notes due 2024.
(4) Relates to costs incurred in the amendment of the senior secured credit facility as described in the Company's Form 10-Q for the three months ended September 30, 2022.
(5) Relates to the loss on the extinguishment of the senior notes due 2026
(6) Relates to certain non-income tax assessments, recoveries and credits
(7) Amounts may not total due to rounding.

 

Contacts

Media Contact:
Gary Kishner
Senior Director, Media Relations
213.745.0456

Investor Contact:
Eric Monroe
Senior Director, Investor Relations
213.745.0449

EX-99 3 a52955832_ex992.htm EXHIBIT 99.2
Exhibit 99.2

Herbalife Nutrition Announces Leadership Change

Longtime Herbalife Nutrition Executive Michael O. Johnson Named Chairman of the Board and Interim Chief Executive Officer

LOS ANGELES--(BUSINESS WIRE)--October 31, 2022--The Board of Directors of Herbalife Nutrition (“Board”) announced that Michael O. Johnson, current member of the Board and the former Chairman and CEO of Herbalife Nutrition (“Company”), has been named Chairman and interim Chief Executive Officer, succeeding Dr. John Agwunobi, who is departing the company.

The Company expects to name a new CEO in 2023.

Mr. Johnson brings more than 40 years of experience leading multi-national corporations, including close to two decades of leading Herbalife Nutrition. Known for his deep expertise in building brands, Mr. Johnson has a proven track record in innovation, motivation, and growth.

“Michael’s vision, intellect and passion for Herbalife Nutrition make him uniquely qualified to lead Herbalife at this time,” said Alan LeFevre, lead independent director of Herbalife Nutrition’s Board of Directors. “His past success of growing the business, combined with his relationships with the Company’s independent distributors, experienced management team, employees and investors, will help the Company accelerate growth and unlock additional opportunities.”

“I have been fortunate to be a part of this iconic brand for close to two decades and I am excited for the opportunities ahead. For more than 40 years, Herbalife Nutrition has been transforming people’s lives by providing them with personalized nutrition and an economic opportunity that is the best in the industry. This commitment to improving communities around the globe is needed now more than ever and while we are proud of our past, we are even more excited about our future,” said Mr. Johnson. “We have hard work ahead of us, but our entrepreneurial and successful business model is resilient, our independent distributors are a powerful engine for continued growth and our dedicated employees are motivated and committed.”

Mr. LeFevre continued, “On behalf of all of us at Herbalife Nutrition, we thank Dr. Agwunobi for his service and commitment to the Company over the past seven years and wish him success in his personal and professional endeavors.”

In a separate press release, today the Company also is announcing third quarter 2022 earnings results. That press release can be found at https://ir.herbalife.com/.

About Michael O. Johnson

Michael O. Johnson is an accomplished business leader with extensive experience expanding companies globally and spearheading successful business transformations. He served as CEO of Herbalife Nutrition from 2003 to 2017, Chairman from 2007 to early 2020, and CEO from 2019 to early 2020. During Mr. Johnson’s tenure as CEO of Herbalife Nutrition, the Company quadrupled sales and expanded its operations around the world from 58 to 95 markets. Under Mr. Johnson’s leadership, Herbalife Nutrition’s product portfolio and R&D function significantly increased, including the development and introduction of the Herbalife24 line of sports nutrition products. Additionally, he drove many of the Company’s key marketing initiatives, including the sponsorship of more than 200 athletes and teams around the globe.


As a member of the Board of Directors, his deep understanding of Herbalife Nutrition, independent distributors, and customers is invaluable for the future growth and development of the Company. Mr. Johnson brings decades of experience in corporate leadership and governance, as well as expertise in product innovation and marketing.

Prior to Herbalife Nutrition, Mr. Johnson led multiple departments of Walt Disney as president of those divisions, including Walt Disney International, Walt Disney Asia, and the Worldwide Home Entertainment division of Walt Disney Studios. Before joining Disney, Mr. Johnson gained extensive experience in the publishing industry including a management position at Time Inc. in the early 1980s.

About Herbalife Nutrition Ltd.

Herbalife Nutrition (NYSE: HLF) is a global company that has been changing people’s lives with great nutrition products and a business opportunity for its independent distributors since 1980. The Company offers science-backed products to consumers in 95 markets through entrepreneurial distributors who provide one-on-one coaching and a supportive community that inspires their customers to embrace a healthier, more active lifestyle. Through the Company’s commitment to nourish people, communities and planet, Herbalife Nutrition pledges to achieve 50 million positive impacts – tangible acts of good – by 2030, its 50th anniversary.

For more information, please visit IAmHerbalifeNutrition.com.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Although we believe that the expectations reflected in any of our forward-looking statements are reasonable, actual results or outcomes could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and to inherent risks and uncertainties, many of which are beyond our control. Additionally, many of these risks and uncertainties are, and may continue to be, amplified by the COVID-19 pandemic. Important factors that could cause our actual results, performance and achievements, or industry results to differ materially from estimates or projections contained in or implied by our forward-looking statements include the following:


  • the potential impacts of the COVID-19 pandemic and current global economic conditions, including inflation, on us; our Members, customers, and supply chain; and the world economy;
  • our ability to attract and retain Members;
  • our relationship with, and our ability to influence the actions of, our Members;
  • our noncompliance with, or improper action by our employees or Members in violation of, applicable U.S. and foreign laws, rules, and regulations;
  • adverse publicity associated with our Company or the direct-selling industry, including our ability to comfort the marketplace and regulators regarding our compliance with applicable laws;
  • changing consumer preferences and demands and evolving industry standards, including with respect to climate change, sustainability, and other environmental, social, and governance, or ESG, matters;
  • the competitive nature of our business and industry;
  • legal and regulatory matters, including regulatory actions concerning, or legal challenges to, our products or network marketing program and product liability claims;
  • the Consent Order entered into with the FTC, the effects thereof and any failure to comply therewith;
  • risks associated with operating internationally and in China;
  • our ability to execute our growth and other strategic initiatives, including implementation of our transformation program and increased penetration of our existing markets;
  • any material disruption to our business caused by natural disasters, other catastrophic events, acts of war or terrorism, including the war in Ukraine, cybersecurity incidents, pandemics, and/or other acts by third parties;
  • our ability to adequately source ingredients, packaging materials, and other raw materials and manufacture and distribute our products;
  • our reliance on our information technology infrastructure;
  • noncompliance by us or our Members with any privacy laws, rules, or regulations or any security breach involving the misappropriation, loss, or other unauthorized use or disclosure of confidential information;
  • contractual limitations on our ability to expand or change our direct-selling business model;
  • the sufficiency of our trademarks and other intellectual property;
  • product concentration;
  • our reliance upon, or the loss or departure of any member of, our senior management team;
  • restrictions imposed by covenants in the agreements governing our indebtedness;
  • risks related to our convertible notes;
  • changes in, and uncertainties relating to, the application of transfer pricing, income tax, customs duties, value added taxes, and other tax laws, treaties, and regulations, or their interpretation;
  • our incorporation under the laws of the Cayman Islands; and
  • share price volatility related to, among other things, speculative trading and certain traders shorting our common shares.

We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.

Contacts

Gary Kishner
Sr. Director, Public Relations
213.745.0456
Garyki@herbalife.com

EX-101.SCH 4 hlf-20221026.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 hlf-20221026_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 6 hlf-20221026_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information
Oct. 26, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 26, 2022
Entity Registrant Name Herbalife Nutrition Ltd.
Entity Incorporation, State or Country Code E9
Entity File Number 1-32381
Entity Tax Identification Number 98-0377871
Entity Address, Address Line One P.O. Box 309, Ugland House
Entity Address, City or Town Grand Cayman
Entity Address, Country KY
Entity Address, Postal Zip Code KY1-1104
City Area Code 213
Local Phone Number 745-0500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0001180262
Title of 12(b) Security Common Shares
Trading Symbol HLF
Security Exchange Name NYSE
XML 8 a52955832_htm.xml IDEA: XBRL DOCUMENT 0001180262 2022-10-26 2022-10-26 false 0001180262 8-K 2022-10-26 Herbalife Nutrition Ltd. E9 1-32381 98-0377871 P.O. Box 309, Ugland House Grand Cayman KY KY1-1104 213 745-0500 false false false false Common Shares HLF NYSE false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 22 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://herbalife.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports a52955832.htm a52955832_ex991.htm a52955832_ex992.htm hlf-20221026.xsd hlf-20221026_lab.xml hlf-20221026_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a52955832.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "a52955832.htm" ] }, "labelLink": { "local": [ "hlf-20221026_lab.xml" ] }, "presentationLink": { "local": [ "hlf-20221026_pre.xml" ] }, "schema": { "local": [ "hlf-20221026.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "hlf", "nsuri": "http://herbalife.com/20221026", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a52955832.htm", "contextRef": "c20221026to20221026", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://herbalife.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a52955832.htm", "contextRef": "c20221026to20221026", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://herbalife.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://herbalife.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://herbalife.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://herbalife.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://herbalife.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://herbalife.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://herbalife.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://herbalife.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://herbalife.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://herbalife.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://herbalife.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://herbalife.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://herbalife.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://herbalife.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://herbalife.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://herbalife.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://herbalife.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://herbalife.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://herbalife.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://herbalife.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://herbalife.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://herbalife.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://herbalife.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://herbalife.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://herbalife.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://herbalife.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://herbalife.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://herbalife.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001157523-22-001444-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001157523-22-001444-xbrl.zip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end